Moyu Hasegawa, Kenji Miki, Takuji Kawamura, Ikue Takei Sasozaki, Yuki Higashiyama, Masaru Tsuchida, Kunio Kashino, Masaki Taira, Emiko Ito, Maki Takeda, Hidekazu Ishida, Shuichiro Higo, Yasushi Sakata, Shigeru Miyagawa
Research on cardiomyopathy models using engineered heart tissue (EHT) created from disease-specific induced pluripotent stem cells (iPSCs) is advancing rapidly. However, the study of restrictive cardiomyopathy (RCM), a rare and intractable cardiomyopathy, remains at the experimental stage because there is currently no established method to replicate the hallmark phenotype of RCM, particularly diastolic dysfunction, in vitro. In this study, we generated iPSCs from a patient with early childhood-onset RCM harboring the TNNI3 R170W mutation (R170W-iPSCs)...
January 9, 2024: Development, Growth & Differentiation